TrivarX Limited (MDBIF) Stock Price & Analysis
TrivarX Limited (MDBIF) — price $0.0029 (0.00%), as of the Nov 19, 2026 trading session; market cap $3.35M.
Educational signal · not a buy or sell recommendation · How to read this
TrivarX Limited · MDBIF
TrivarX Limited (MDBIF) is a health technology company specializing in AI-driven diagnostic tools for behavioral health disorders.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0029 | |
| Change on the day | 0.00% | |
| Market capitalisation | $3.35M | |
| Shares traded on the day | 20.0K |
Price & events
Other perspectives
Council score for TrivarX (MDBIF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
2 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is TrivarX (MDBIF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. TrivarX Limited (MDBIF) is the company analyzed here. In Q4 FY2025 it reported revenue of A$278 and net income of -A$852,148. The market values it at $3.35M.
What do the latest results show for TrivarX (MDBIF)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of A$278.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | A$278 | -A$852,148 | -A$0.0016 (diluted) |
| Q2 FY2025 | A$1M | -A$91,083 | -A$0.0002 (diluted) |
What are the financial strengths and risks for TrivarX (MDBIF)?
Short answer · as of
The distress and quality screens read Altman Z -5.80 · Piotroski F 3. Trailing ratios: ROE -44.3% · ROA -53.0% · current ratio 5.26 · free-cash-flow yield -4.7%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -5.80 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-44.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MDBIF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported MDBIF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: MDBIF Stock
These answers are editorial: 1 of these 1 answer is drawn from the MDBIF research dossier (written Jun 15, 2026 by gpt-4o-mini). Figures in this section are not part of the source register.
What are the key growth opportunities for MDBIF in healthcare?
TrivarX Limited has several growth opportunities, including expansion into the U.S. market, where the demand for mental health solutions is increasing. The company can leverage its AI-driven diagnostic tools to capture market share and enhance its product offerings.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 10 figures on this page — 8 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com